What should I know first?
The term commonly refers to insufficient benefit from at least two adequately tried antidepressants. Clinicians review the dose, duration, adherence and diagnosis before concluding that a treatment has failed. Definitions and eligibility criteria differ across research, medicine licences and services.
Important Distinctions
Treatment resistance does not mean that recovery is impossible or that a person has failed. Options may include psychological treatment, changes to medicines, augmentation and brain stimulation. Eligibility for ketamine or esketamine requires a separate clinical assessment and country-specific information.
Sources and References
- Depression: treatment and brain stimulation options
- Spravato: current US prescribing information (revised March 2026)
- Spravato 28 mg nasal spray: UK Summary of Product Characteristics
Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.
Article Information
- Content updated
- 2026-10-19
- Sources checked
- 2026-10-19
- Publication status
- Published

